Cargando…

THU080 Splicing Machinery Dysregulation As A Source Of Novel Diagnostic, Prognostic And Therapeutic Targets In Craniopharyngiomas

Disclosure: A.C. Fuentes-Fayos: None. M.E. Garcia-Garcia: None. D. Cano: None. A.J. Martínez-Fuentes: None. I. Di Caro: None. M.D. Gahete: None. J.P. Castaño: None. J.P. Martínez-Barbera: None. A. Soto-Moreno: None. M.A. Galvez-Moreno: None. J.M. Jimenez-Vacas: None. R.M. Luque: None. Craniopharyngi...

Descripción completa

Detalles Bibliográficos
Autores principales: Fuentes-Fayos, Antonio C, Garcia-Garcia, Miguel E, Cano, David, Martínez-Fuentes, Antonio J, Di Caro, Isidoro, Gahete, Manuel D, Castaño, Justo P, Martínez-Barbera, Juan P, Soto-Moreno, Alfonso, Galvez-Moreno, Maria A, Jimenez-Vacas, Juan M, Luque, Raul M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554208/
http://dx.doi.org/10.1210/jendso/bvad114.1160
_version_ 1785116357468094464
author Fuentes-Fayos, Antonio C
Garcia-Garcia, Miguel E
Cano, David
Martínez-Fuentes, Antonio J
Di Caro, Isidoro
Gahete, Manuel D
Castaño, Justo P
Martínez-Barbera, Juan P
Soto-Moreno, Alfonso
Galvez-Moreno, Maria A
Jimenez-Vacas, Juan M
Luque, Raul M
author_facet Fuentes-Fayos, Antonio C
Garcia-Garcia, Miguel E
Cano, David
Martínez-Fuentes, Antonio J
Di Caro, Isidoro
Gahete, Manuel D
Castaño, Justo P
Martínez-Barbera, Juan P
Soto-Moreno, Alfonso
Galvez-Moreno, Maria A
Jimenez-Vacas, Juan M
Luque, Raul M
author_sort Fuentes-Fayos, Antonio C
collection PubMed
description Disclosure: A.C. Fuentes-Fayos: None. M.E. Garcia-Garcia: None. D. Cano: None. A.J. Martínez-Fuentes: None. I. Di Caro: None. M.D. Gahete: None. J.P. Castaño: None. J.P. Martínez-Barbera: None. A. Soto-Moreno: None. M.A. Galvez-Moreno: None. J.M. Jimenez-Vacas: None. R.M. Luque: None. Craniopharyngiomas (CP) are relatively benign epithelial tumors that typically arise in the sellar/suprasellar region, and are classified in adamantinomatous (ACP) and papillary (PCP). Diagnosis is usually performed when tumor development is already advanced, and serious comorbidities are present. The first-line therapy is usually surgery, but frequently the resection is not complete, causing high recurrence rates. Therefore, the identification of alternative diagnostic/prognostic/therapeutic tools to improve CP management is necessary. Recently, growing evidence indicates that defects in the splicing-process are frequent in cancer, leading to the appearance of altered spliceosome components (SCs), splicing-factors (SFs) and/or aberrant splicing-variants (SVs), which are associated with the development/progression/aggressiveness of various cancer types. Therefore, our aim was to explore the putative oncogenic role of key splicing-related factors in CP through: 1) interrogating the expression profile of key splicing machinery components in ACP (n=36) and PCP (n=4) vs. control samples [n=11; normal-pituitaries (NP)]; and 2) implementing different bioinformatic and functional approaches (RNAseq and CP primary cell-cultures). Our results revealed a substantial number of SCs and SFs drastically altered in ACP vs. NP, and also when primary vs. recurrent ACP were compared. Specifically, 4 SFs were identified as the most discriminating diagnostic/prognostic factors, being corroborated in additional human cohorts, and associated with key clinical parameters suggesting a potential oncogenic role in CP. Dysregulation of 2 of these SFs was also corroborated in RNAseq of an additional cohort of 18 ACP vs. 3 NP. In vitro overexpression of these SFs in primary ACP-derived cells revealed a critical functional role of these factors in ACP. In fact, this overexpression induced the phosphorylation of MAPK and AKT pathways and reduced the phosphorylation JAK/STAT, NF-kB and TGFB that could be involved in the CP tumorigenesis. Finally, key SVs that are associated to CP development/progression (e.g., GNAS) were identified as potential oncogenic linkers with the observed splicing-machinery dysregulation. In conclusion, spliceosome is drastically altered in CP wherein some SFs could represent attractive novel diagnostic/prognostic and therapeutic targets for this endocrine pathology. Funding: Junta de Andalucia (PEER-0048-2020, Cofunded by EU-Programa Operativo FEDER 2014-2020). Presentation: Thursday, June 15, 2023
format Online
Article
Text
id pubmed-10554208
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-105542082023-10-06 THU080 Splicing Machinery Dysregulation As A Source Of Novel Diagnostic, Prognostic And Therapeutic Targets In Craniopharyngiomas Fuentes-Fayos, Antonio C Garcia-Garcia, Miguel E Cano, David Martínez-Fuentes, Antonio J Di Caro, Isidoro Gahete, Manuel D Castaño, Justo P Martínez-Barbera, Juan P Soto-Moreno, Alfonso Galvez-Moreno, Maria A Jimenez-Vacas, Juan M Luque, Raul M J Endocr Soc Neuroendocrinology & Pituitary Disclosure: A.C. Fuentes-Fayos: None. M.E. Garcia-Garcia: None. D. Cano: None. A.J. Martínez-Fuentes: None. I. Di Caro: None. M.D. Gahete: None. J.P. Castaño: None. J.P. Martínez-Barbera: None. A. Soto-Moreno: None. M.A. Galvez-Moreno: None. J.M. Jimenez-Vacas: None. R.M. Luque: None. Craniopharyngiomas (CP) are relatively benign epithelial tumors that typically arise in the sellar/suprasellar region, and are classified in adamantinomatous (ACP) and papillary (PCP). Diagnosis is usually performed when tumor development is already advanced, and serious comorbidities are present. The first-line therapy is usually surgery, but frequently the resection is not complete, causing high recurrence rates. Therefore, the identification of alternative diagnostic/prognostic/therapeutic tools to improve CP management is necessary. Recently, growing evidence indicates that defects in the splicing-process are frequent in cancer, leading to the appearance of altered spliceosome components (SCs), splicing-factors (SFs) and/or aberrant splicing-variants (SVs), which are associated with the development/progression/aggressiveness of various cancer types. Therefore, our aim was to explore the putative oncogenic role of key splicing-related factors in CP through: 1) interrogating the expression profile of key splicing machinery components in ACP (n=36) and PCP (n=4) vs. control samples [n=11; normal-pituitaries (NP)]; and 2) implementing different bioinformatic and functional approaches (RNAseq and CP primary cell-cultures). Our results revealed a substantial number of SCs and SFs drastically altered in ACP vs. NP, and also when primary vs. recurrent ACP were compared. Specifically, 4 SFs were identified as the most discriminating diagnostic/prognostic factors, being corroborated in additional human cohorts, and associated with key clinical parameters suggesting a potential oncogenic role in CP. Dysregulation of 2 of these SFs was also corroborated in RNAseq of an additional cohort of 18 ACP vs. 3 NP. In vitro overexpression of these SFs in primary ACP-derived cells revealed a critical functional role of these factors in ACP. In fact, this overexpression induced the phosphorylation of MAPK and AKT pathways and reduced the phosphorylation JAK/STAT, NF-kB and TGFB that could be involved in the CP tumorigenesis. Finally, key SVs that are associated to CP development/progression (e.g., GNAS) were identified as potential oncogenic linkers with the observed splicing-machinery dysregulation. In conclusion, spliceosome is drastically altered in CP wherein some SFs could represent attractive novel diagnostic/prognostic and therapeutic targets for this endocrine pathology. Funding: Junta de Andalucia (PEER-0048-2020, Cofunded by EU-Programa Operativo FEDER 2014-2020). Presentation: Thursday, June 15, 2023 Oxford University Press 2023-10-05 /pmc/articles/PMC10554208/ http://dx.doi.org/10.1210/jendso/bvad114.1160 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Neuroendocrinology & Pituitary
Fuentes-Fayos, Antonio C
Garcia-Garcia, Miguel E
Cano, David
Martínez-Fuentes, Antonio J
Di Caro, Isidoro
Gahete, Manuel D
Castaño, Justo P
Martínez-Barbera, Juan P
Soto-Moreno, Alfonso
Galvez-Moreno, Maria A
Jimenez-Vacas, Juan M
Luque, Raul M
THU080 Splicing Machinery Dysregulation As A Source Of Novel Diagnostic, Prognostic And Therapeutic Targets In Craniopharyngiomas
title THU080 Splicing Machinery Dysregulation As A Source Of Novel Diagnostic, Prognostic And Therapeutic Targets In Craniopharyngiomas
title_full THU080 Splicing Machinery Dysregulation As A Source Of Novel Diagnostic, Prognostic And Therapeutic Targets In Craniopharyngiomas
title_fullStr THU080 Splicing Machinery Dysregulation As A Source Of Novel Diagnostic, Prognostic And Therapeutic Targets In Craniopharyngiomas
title_full_unstemmed THU080 Splicing Machinery Dysregulation As A Source Of Novel Diagnostic, Prognostic And Therapeutic Targets In Craniopharyngiomas
title_short THU080 Splicing Machinery Dysregulation As A Source Of Novel Diagnostic, Prognostic And Therapeutic Targets In Craniopharyngiomas
title_sort thu080 splicing machinery dysregulation as a source of novel diagnostic, prognostic and therapeutic targets in craniopharyngiomas
topic Neuroendocrinology & Pituitary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554208/
http://dx.doi.org/10.1210/jendso/bvad114.1160
work_keys_str_mv AT fuentesfayosantonioc thu080splicingmachinerydysregulationasasourceofnoveldiagnosticprognosticandtherapeutictargetsincraniopharyngiomas
AT garciagarciamiguele thu080splicingmachinerydysregulationasasourceofnoveldiagnosticprognosticandtherapeutictargetsincraniopharyngiomas
AT canodavid thu080splicingmachinerydysregulationasasourceofnoveldiagnosticprognosticandtherapeutictargetsincraniopharyngiomas
AT martinezfuentesantonioj thu080splicingmachinerydysregulationasasourceofnoveldiagnosticprognosticandtherapeutictargetsincraniopharyngiomas
AT dicaroisidoro thu080splicingmachinerydysregulationasasourceofnoveldiagnosticprognosticandtherapeutictargetsincraniopharyngiomas
AT gahetemanueld thu080splicingmachinerydysregulationasasourceofnoveldiagnosticprognosticandtherapeutictargetsincraniopharyngiomas
AT castanojustop thu080splicingmachinerydysregulationasasourceofnoveldiagnosticprognosticandtherapeutictargetsincraniopharyngiomas
AT martinezbarberajuanp thu080splicingmachinerydysregulationasasourceofnoveldiagnosticprognosticandtherapeutictargetsincraniopharyngiomas
AT sotomorenoalfonso thu080splicingmachinerydysregulationasasourceofnoveldiagnosticprognosticandtherapeutictargetsincraniopharyngiomas
AT galvezmorenomariaa thu080splicingmachinerydysregulationasasourceofnoveldiagnosticprognosticandtherapeutictargetsincraniopharyngiomas
AT jimenezvacasjuanm thu080splicingmachinerydysregulationasasourceofnoveldiagnosticprognosticandtherapeutictargetsincraniopharyngiomas
AT luqueraulm thu080splicingmachinerydysregulationasasourceofnoveldiagnosticprognosticandtherapeutictargetsincraniopharyngiomas